BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26037622)

  • 1. Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.
    Hofer J; Giner T; Cortina G; Jungraithmayr T; Masalskiene J; Dobiliene D; Mitkiene R; Pundziene B; Rudaitis S
    Pediatr Transplant; 2015 Aug; 19(5):E121-5. PubMed ID: 26037622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome.
    Khandelwal P; Sinha A; Hari P; Bansal VK; Dinda AK; Bagga A
    Pediatr Transplant; 2014 Aug; 18(5):E134-9. PubMed ID: 24814615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
    Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
    Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J; Giner T; Józsi M
    Semin Thromb Hemost; 2014 Jun; 40(4):431-43. PubMed ID: 24799303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
    Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency.
    Gonzales E; Ulinski T; Habes D; Deschênes G; Frémeaux-Bacchi V; Bensman A
    Pediatr Nephrol; 2016 Dec; 31(12):2375-2378. PubMed ID: 27744619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.
    Kasapoğlu U; Ruhi Ç; Tuğcu M; Boynueğri B; Titiz İ; Hançer VS; Apaydın S
    Ann Transplant; 2015 Dec; 20():714-9. PubMed ID: 26621268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation.
    Kim S; Park E; Min SI; Yi NJ; Ha J; Ha IS; Cheong HI; Kang HG
    J Korean Med Sci; 2018 Jan; 33(1):e4. PubMed ID: 29215813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.
    Zlamy M; Hofer J; Elias J; Vogel U; Frosch M; Jungraithmayr T; Zimmerhackl LB; Prelog M
    Pediatr Transplant; 2012 Sep; 16(6):E246-50. PubMed ID: 21967634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetics of aHUS and transplant recurrence].
    Bresin E
    G Ital Nefrol; 2015; 32 Suppl 64():. PubMed ID: 26479051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report.
    Albertazzi V; Bonucchi D; De Amicis S; Americo C; Ghiandai G; Cappelli G
    Transplant Proc; 2010 May; 42(4):1352-4. PubMed ID: 20534299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.
    Stevenson S; Mallett A; Oliver K; Hyland V; Hawley C; Malmanche T; Isbel N
    Nephrology (Carlton); 2014 Apr; 19 Suppl 1():22-6. PubMed ID: 24460647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation.
    Kawaguchi K; Kawanishi K; Sato M; Itabashi M; Fujii A; Kanetsuna Y; Huchinoue S; Ohashi R; Koike J; Honda K; Nagashima Y; Nitta K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():61-5. PubMed ID: 26031589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.
    Sinibaldi S; Guzzo I; Piras R; Bresin E; Emma F; Dello Strologo L
    Pediatr Transplant; 2013 Dec; 17(8):E177-81. PubMed ID: 24118826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS.
    Hofer J; Riedl Khursigara M; Perl M; Giner T; Rosales A; Cortina G; Waldegger S; Jungraithmayr T; Würzner R
    Pediatr Nephrol; 2021 Apr; 36(4):917-925. PubMed ID: 33025207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.